Home / Market News / $QGEN

$QGEN news and market catalysts

The 20 most recent market catalysts affecting $QGEN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

20 catalysts 5 high impact 9 bullish 5 bearish Biotechnology
Nov 9, 2026 Corporate Catalyst Bearish Impact 95
QIAGEN Reports Q3 2026 Financial Results and Suspends Guidance Amid EQT Offer
QIAGEN's Q3 2026 results show a 2.8% revenue increase and improved adjusted EPS, indicating solid operational performance. However, the suspension of 2026 guidance due to EQT's €46…
Oct 29, 2026 Corporate Catalyst Bullish Impact 55
Parse Biosciences and Nomic Bio Announce Partnership for Immune Biology Dataset
Parse Biosciences (a QIAGEN company) and Nomic Bio have announced a strategic partnership to develop 'Cascade,' a 100 million-cell immune biology dataset. This initiative combines …
Oct 28, 2026 Corporate Catalyst Neutral Impact 65
Brodsky & Smith Investigates Proposed Acquisition of QIAGEN N.V.
Brodsky & Smith LLC has launched an investigation into the proposed acquisition of QIAGEN N.V. by EQT Private Equity. The core concern is whether QIAGEN's board fulfilled its fiduc…
Oct 28, 2026 Corporate Catalyst Bearish Impact 65
Barclays Downgrades QIAGEN to Equal Weight
Barclays Capital downgraded QIAGEN N.V. to 'Equal Weight' from 'Overweight' and reduced its price target from $55 to $53. This move is significant because it signals that Barclays …
Oct 23, 2026 Corporate Catalyst Bearish Impact 65
Baird Downgrades QIAGEN to Neutral
Analyst firm Baird downgraded QIAGEN N.V. from an 'Outperform' rating to 'Neutral' and established a price target of $52 per share. This action signals a reduced level of confidenc…
Oct 22, 2026 Corporate Catalyst Bearish Impact 55
JPMorgan Downgrades QIAGEN to Neutral
JPMorgan has downgraded QIAGEN N.V. from its previous rating to Neutral, setting a new price target of $52. This move signals a more cautious outlook from a major financial institu…
Oct 22, 2026 Corporate Catalyst Neutral Impact 65
Perella Weinberg Partners Serves as Financial Advisor to QIAGEN Supervisory Board
The filing confirms Perella Weinberg Partners' role as financial advisor to QIAGEN's Supervisory Board for the company's $10.8 billion acquisition by EQT. This is a significant man…
Oct 22, 2026 Corporate Catalyst Bullish Impact 55
Berenberg Adjusts Price Target for QIAGEN
Berenberg, an analyst firm, has updated its outlook on QIAGEN N.V. by raising its price target from $45.50 to $52.22. This revision comes after an announced acquisition agreement, …
Oct 22, 2026 Corporate Catalyst Bullish Impact 95
QIAGEN Agrees to Acquisition by EQT for $12.1 Billion
QIAGEN N.V. has agreed to be acquired by Swedish private equity group EQT for $12.1 billion in an all-cash deal. This is a major corporate catalyst for QIAGEN, as it represents a d…
Oct 20, 2026 Corporate Catalyst Bullish Impact 85
Qiagen shares are trading higher following a report suggesting that EQT AB is in advanced talks to acquire the company.
The news of EQT AB being in advanced talks to acquire Qiagen is a major corporate catalyst. This typically results in a significant upward movement in the target company's stock (Q…
Oct 20, 2026 Corporate Catalyst Neutral Impact 95
'EQT Is in Advanced Talks to Buy Testing Firm Qiagen' - Bloomberg
The Bloomberg article, linked in the filing, reports that EQT is in advanced talks to acquire Qiagen. This potential acquisition is a major corporate catalyst, as it would involve …
Oct 13, 2026 Corporate Catalyst Neutral Impact 75
Qiagen Says Over 160M QuantiFERON-TB Tests Sold Since Launch As It Hosts Global TB Summit October 13-16
The headline is a strong corporate catalyst for Qiagen (QGEN), highlighting significant commercial success for its QuantiFERON-TB test with over 160 million units sold. This indica…
Oct 6, 2026 Corporate Catalyst Bullish Impact 65
Barclays Upgrades Qiagen to Overweight, Raises Price Target to $55
Barclays' upgrade of Qiagen to Overweight and the significant increase in its price target from $40 to $55 signals a strong vote of confidence from a major financial institution. T…
Sep 24, 2026 Corporate Catalyst Neutral Impact 65
Qiagen Launches QIAmini Benchtop System To Automate DNA And RNA Extraction For Smaller Research Labs
This headline represents a moderate corporate catalyst for Qiagen (QGEN) as it introduces a new product designed to capture a previously underserved market segment – smaller resear…
Sep 9, 2026 Corporate Catalyst Bearish Impact 55
UBS Maintains Neutral on Qiagen, Lowers Price Target to $47
UBS analyst Dan Leonard maintained a 'Neutral' rating on Qiagen but lowered the price target from $52 to $47. This action indicates that while the analyst doesn't see a strong reas…
Aug 24, 2026 Corporate Catalyst Neutral Impact 75
QIAGEN Appoints Jonathan M. Pratt CEO, Effective Sept. 1, Succeeding Thierry Bernard; Co. Reiterates Q3, FY26 Guidance
QIAGEN announced a significant leadership change with Jonathan M. Pratt taking over as CEO in September 2026. This is a notable corporate event, as a new CEO often brings strategic…
Aug 10, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Neutral on Qiagen, Raises Price Target to $45
Citigroup analyst Brendan Digan has updated their outlook on Qiagen, raising the price target from $38 to $45 while keeping a 'Neutral' rating. This indicates that while the analys…
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $50
JP Morgan analyst Casey Woodring has maintained an 'Overweight' rating on Qiagen (QGEN) and raised the price target from $45 to $50. This action signals increased confidence from a…
Aug 5, 2026 Corporate Catalyst Bullish Impact 92
Qiagen Q2 Adj. EPS $0.62 Beats $0.60 Estimate, Sales $535.000M Beat $527.484M Estimate
Qiagen announced its Q2 earnings, reporting adjusted EPS of $0.62, which surpassed the analyst consensus of $0.60, and sales of $535 million, exceeding the $527.484 million estimat…
Jul 15, 2026 Corporate Catalyst Bullish Impact 55
Qiagen Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak; Says Qiagen’s FDA-Cleared QIAstat-Dx Gastrointestinal Panel 2 Can Detect Cyclospora Infections In About An Hour As Part Of A 16-Target Gastrointestinal Pathogens Menu
Qiagen is leveraging a public health crisis, the growing Cyclospora outbreak in the U.S., to highlight its relevant diagnostic products. This is a positive development for Qiagen a…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.